Skip to content
10-K

Annual Report

NORTHWEST BIOTHERAPEUTICS INC NWBO

0001104659-26-043806

← back to feed
Filed
Apr 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 31, 2026 1.61B sh
Stock Issued FY 2025 · Dec 31, 2025 88.1M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.46B sh
Shares Diluted restated FY 2025 · Dec 31, 2024 1.24B sh
Capex FY 2025 · Dec 31, 2025 $1.5M
Capex FY 2025 · Dec 31, 2024 $1.01M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$44.76M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$57.02M
Long Term Debt FY 2025 · Dec 31, 2025 $60.04M
Long Term Debt FY 2025 · Dec 31, 2024 $62.68M
Cash And Equivalents FY 2025 · Dec 31, 2025 $3.04M
Cash And Equivalents FY 2025 · Dec 31, 2024 $2.18M
Stockholders Equity FY 2025 · Dec 31, 2025 −$60.28M
Stockholders Equity FY 2025 · Dec 31, 2024 −$94.49M
Stockholders Equity FY 2025 · Dec 31, 2023 −$65.77M
Current Liabilities FY 2025 · Dec 31, 2025 $91.7M
Current Liabilities FY 2025 · Dec 31, 2024 $68.27M
Total Liabilities FY 2025 · Dec 31, 2025 $128.86M
Total Liabilities FY 2025 · Dec 31, 2024 $105.71M
Current Assets FY 2025 · Dec 31, 2025 $5.52M
Current Assets FY 2025 · Dec 31, 2024 $4.06M
Total Assets FY 2025 · Dec 31, 2025 $81.29M
Total Assets FY 2025 · Dec 31, 2024 $26.73M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.04
Eps Diluted FY 2025 · Dec 31, 2024 −$0.07
Eps Basic FY 2025 · Dec 31, 2025 −$0.04
Eps Basic FY 2025 · Dec 31, 2024 −$0.07
Sga Expense FY 2025 · Dec 31, 2025 $32.51M
Sga Expense FY 2025 · Dec 31, 2024 $33M
Rd Expense FY 2025 · Dec 31, 2025 $28.79M
Rd Expense FY 2025 · Dec 31, 2024 $34.89M
Net Income FY 2025 · Dec 31, 2025 −$60.16M
Net Income FY 2025 · Dec 31, 2024 −$83.78M
Operating Income FY 2025 · Dec 31, 2025 −$59.91M
Operating Income FY 2025 · Dec 31, 2024 −$66.51M
Revenue FY 2025 · Dec 31, 2025 $1.38M
Revenue FY 2025 · Dec 31, 2024 $1.38M